🧭Clinical Trial Compass

Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential (NCT03291652) | Clinical Trial Compass

RecruitingNot Applicable

Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential

Hong Kong140 participantsStarted 2010-02

Plain-language summary

The study is to attain early recognition of the unstable plaques which have an imminent embolic risk in patients with intracranial atherosclerotic disease (IAD).

Who can participate

Age range30 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient is 30 to 85 years of age, inclusive.
✓. Patients who have an acute infarct in diffusion-weighted MRI compatible with artery-to-artery thrombo-embolism, a relevant intracranial atherosclerotic stenosis ≥60%, and MES detected by TCD.
✓. Patient who has no contra-indication for the proposed imaging tests.
✓. Patient understands the purpose and requirements of the study, and has provided an informed consent.
✓. Patient is 30 to 85 years of age, inclusive.
✓. Patient who has a high-grade (\>60%) intracranial stenosis (signal void in MR angiography) but without infarct in the corresponding vascular territory in DWI or T2-weighted sequence.
✓. Patient has no MES detected on TCD examination.
✓. Patient who has no contra-indication for the proposed imaging tests.

Exclusion criteria

✕. Stroke etiology uncertain or unrelated to intracranial atherosclerosis, such as cardioembolism, Moyamoya disease, small vessel disease, etc.
✕. A tandem stenosis \>50% at proximal internal carotid artery.
✕. Bleeding propensity: active peptic ulcer disease, major systemic hemorrhage within 30 days, thrombocytopenia (platelets \<100 x 109/L), coagulopathy (INR \>1.5).
✕. A medical condition that would not allow the patient to adhere to the protocol or complete the study.

What they're measuring

1

The plaque morphology of high-risk IAD may be distinct from the silent ones.

Timeframe: Dec, 2020

Trial details

NCT IDNCT03291652

SponsorChinese University of Hong Kong

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-23

Contact for this trial

Thomas Wai Hong LEUNG, FRCP

852-35053593 drtleung@cuhk.edu.hk

View on ClinicalTrials.gov More Ischemic Stroke trials